Methamphetamine dependence is a widespread problem that crosses socioeconomic boundaries and causes substantial medical morbidity and economic burden. This project uses genetics and neuroimaging techniques to investigate the neurobiology of addiction to methamphetamine as it relates to the TAAR1 trace amine receptor. We hypothesize that individuals with a common TAAR1 genetic variant (v288v) will have a blunted response to methamphetamine on tests of attention and cognitive control as well as on striato-limbic resting state functional connectivity (RSFC). SA 1. Determine the influence of htaar1 common variant (CV) vs. wild type (WT) genotype on RSFC and craving in chronic MUD. SA 2: Determine the effect of acute oral MA or placebo (PBO) administration on the interaction of htaar1 CV vs. WT genotype on RSFC, craving, cognitive control, attention and subjective experience in MUD. This project will consent and enroll up to 100 subjects who will be screened for TAAR1 genotype and placed into one of two groups: one which will include subjects who are wild type (WT) for the TAAR1 gene and those who are either homozygous or heterozygous for the CV, v288v. Others will be screened out of the study. A partner lab will determine genotype so that study staff and subjects will be blinded to genotype. Subjects will be administered methamphetamine and placebo in a blinded, randomized manner over two visits and evaluated with resting state fMRI, subjective effects and behavioral tasks. RSFC comparisons of meth versus placebo and comparisons of WT versus CV groups will be evaluated.

Public Health Relevance

Methamphetamine is one of the most commonly abused (non-prescription) substances in the country and dependence has neuropsychiatric, medical, legal and economic costs to individuals and communities. This project seeks to develop a better understanding of acute methamphetamine administration as it's related to trace amine associated receptor (TAAR1) genotype and may lead to better predictors of addiction and novel cognitive and pharmacological interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DA047602-01A1
Application #
9823456
Study Section
Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS)
Program Officer
Pollock, Jonathan D
Project Start
2019-08-01
Project End
2021-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239